Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 (Q78594497)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

title

Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

Dietmar W Siemann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Amyn M Rojiani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

language of work or name

English

0 references

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

15 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

1512-1517

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Angiogenesis as a target for tumor treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Targeting tumor blood vessels: an adjuvant strategy for radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Potentiation of combination chemotherapy by nitroheterocyclics

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903919-6

7 January 2021

10.1016/S0360-3016(02)03919-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12459379%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference